2seventy bio (2seventy bio) ROCE % : -44.42% (As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is 2seventy bio ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. 2seventy bio's annualized ROCE % for the quarter that ended in Dec. 2023 was -44.42%.

2seventy bio ROCE % Historical Data

The historical data trend for 2seventy bio's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

2seventy bio ROCE % Chart

2seventy bio Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROCE %

Get a 7-Day Free Trial

-159.76

-64.53

-69.82

-42.47

-40.04

2seventy bio Quarterly Data
	Dec18	Dec19	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
ROCE %	Get a 7-Day Free Trial												-18.02	-33.25	-29.40	-37.80	-44.42

2seventy bio ROCE % Calculation

2seventy bio's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	-216.703	/	( ( (656.665 - 79.794)	+	(565.426 - 59.779) )	/ 2 )
	=	-216.703	/	( (576.871	+	505.647)	/ 2 )
	=	-216.703	/	541.259
	=	-40.04 %

2seventy bio's ROCE % of for the quarter that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Dec. 2023 )		(Q: Sep. 2023 )		(Q: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Dec. 2023 )		(Q: Sep. 2023 )		(Q: Dec. 2023 )
	=	-239.524	/	( ( (640.806 - 68.008)	+	(565.426 - 59.779) )	/ 2 )
	=	-239.524	/	( ( 572.798	+	505.647 )	/ 2 )
	=	-239.524	/	539.2225
	=	-44.42 %

(1) Note: The EBIT data used here is four times the quarterly (Dec. 2023) EBIT data.

2seventy bio (NAS:TSVT) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

2seventy bio ROCE % Related Terms

Thank you for viewing the detailed overview of 2seventy bio's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

2seventy bio (2seventy bio) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » 2seventy bio Inc (NAS:TSVT) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

N/A

Address

60 Binney Street, Cambridge, MA, USA, 02142

Website

https://www.2seventybio.com

2seventy bio Inc is a cell and gene therapy company focused on the research, development, and commercialization of transformative treatments for cancer. The company operates in a single segment, focusing on researching, developing and commercializing potentially transformative treatments for cancer.

Executives

Nick Leschly	director, officer: President and CEO	C/O BLUEBIRD BIO, INC., 840 MEMORIAL DRIVE, CAMBRIDGE MA 02139
Philip D Gregory	officer: Chief Scientific Officer	POINT RICHMOND TECH CENTER II, 501 CANAL BOULEVARD SUITE A100, RICHMOND CA 94804
Baird William D Iii	officer: Chief Financial Officer	C/O BLUEBIRD BIO, INC., 60 BINNEY STREET, CAMBRIDGE MA 02142
Yue Tang	10 percent owner	221 ELM ROAD, PRINCETON NJ 08540
Kynam Fund Gp, Llc	10 percent owner	221 ELM ROAD, PRINCETON NJ 08540
Kynam Global Healthcare Master Fund, Lp	10 percent owner	221 ELM ROAD, PRINCETON NJ 08540
Kynam Capital Management Gp, Llc	10 percent owner	221 ELM ROAD, PRINCETON NJ 08540
Kynam Capital Management, Lp	10 percent owner	221 ELM ROAD, PRINCETON NJ 08540
Lin Wei	director	C/O ERASCA, INC., 10835 ROAD TO THE CURE, SUITE 140, SAN DIEGO CA 92121
Nicola Heffron	officer: Chief Operating Officer	2SEVENTY BIO, INC., 60 BINNEY STREET, CAMBRIDGE MA 02142
Marcela V. Maus	director	16 RICHMOND CIRCLE, LEXINGTON MA 02421
Ramy Ibrahim	director	C/O SURFACE ONCOLOGY, 50 HAMPSHIRE STREET, 8TH FLOOR, CAMBRIDGE MA 02139
Sarah Js Glickman	director	60 BINNEY STREET, C/O BLUEBIRD BIO, INC., CAMBRIDGE MA 02142
Daniel Lynch	director
Denice Torres	director	3 RABBIT RUN DRIVE, NEW HOPE PA 18938